Genome-wide association studies in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Genome-wide association studies (GWAS) have gained considerable momentum over the last couple of years for the identification of novel complex disease genes. In the field of Alzheimer's disease (AD), there are currently eight published and two provisionally reported GWAS, highlighting over two dozen novel potential susceptibility loci beyond the well-established APOE association. On the basis of the data available at the time of this writing, the most compelling novel GWAS signal has been observed in GAB2 (GRB2-associated binding protein 2), followed by less consistently replicated signals in galanin-like peptide (GALP), piggyBac transposable element derived 1 (PGBD1), tyrosine kinase, non-receptor 1 (TNK1). Furthermore, consistent replication has been recently announced for CLU (clusterin, also known as apolipoprotein J). Finally, there are at least three replicated loci in hitherto uncharacterized genomic intervals on chromosomes 14q32.13, 14q31.2 and 6q24.1 likely implicating the existence of novel AD genes in these regions. In this review, we will discuss the characteristics and potential relevance to pathogenesis of the outcomes of all currently available GWAS in AD. A particular emphasis will be laid on findings with independent data in favor of the original association.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Genetic studies have identified numerous AD risk variants in immune‐ and microglial‐associated genes, highlighting the importance of microglia function in disease progression. 3 , 4 , 5 , 6 , 7”
From Alzheimer's disease–associated PLCG2 variants alter microglial state and function in human induced pluripotent stem cell–derived microglia‐like cells (2025) · cites this paper as [3]
In the citing paper
“In addition, we found the APOE and APP subnetwork within the vesicle mediated transport pathway which are among the most significant genetic risk factors for AD (Figure 5F).46,47,48”
From SCING: Inference of robust, interpretable gene regulatory networks from single cell and spatial transcriptomics (2023) · cites this paper as [46]
Citations
Cites
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 1×
“However, with the exception of one genetic variant, the 14-allele of the apolipoprotein E gene (APOE) (6,7) none of these candidates has been proven to consistently influence disease risk or onset age in more than a handful of samples.”
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., & Hirschhorn, J. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2344 · Cited by 2,891 · cited 1×
“For many genetically complex diseases, the GWAS approach has yielded an unexpectedly large number of genome-wide significant findings that were confirmed by independent follow-up studies (9,10).”
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 3×
“In the quest to uncover the late-onset AD genes, a vast body of data has been accrued over the past 30 years in well over 1200 studies assessing more than 500 different genes as potential risk factors, mostly using a candidate gene-based approach (5).”
InfluentialSelf-citationTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Self-citationThirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747
Self-citationCoon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H., Zismann, V. L., Beach, T. G., Leung, D., Bryden, L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0419 · Cited by 569
Assessment of cumulative evidence on genetic associations: interim guidelines
Ioannidis, J. P., Boffetta, P., Little, J., O'Brien, T. R., Uitterlinden, A. G., Vineis, P., Balding, D. J., Chokkalingam, A., Dolan, S. M., Flanders, W. D., et al. (2008) · International Journal of Epidemiology · doi:10.1093/ije/dym159 · Cited by 552 · cited 2×
“Furthermore, this association is one of the few showing ‘strong’ epidemiologic credibility when applying interim grading criteria of the Human Genome Epidemiology Network (16).”
Research works printed but not linked: 3
- 2007, 54, 713
- 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 150, 50
- 2004, 43, 605
Cited by
Items 101–200 of 287
Bahado-Singh, R. O., Vishweswaraiah, S., Aydas, B., Yılmaz, A., Metpally, R. P. R., Carey, D. J., Crist, R. C., Berrettini, W. H., Wilson, G. D., Imam, K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248375 · Cited by 35
“Genome-wide association studies (GWAS) [8] have identified several LOADassociated risk loci [9] proliferation in peripheral blood leukocytes including in T-lymphocytes [10], B-lymphocytes [11], polymorphonuclear leucocytes [12], monocytes, and macrophages [13] have been reported.”
BackgroundAssociation of Apolipoprotein E in Lipoprotein Subspecies With Risk of Dementia
Koch, M., DeKosky, S. T., Goodman, M., Sun, J., Furtado, J. D., Fitzpatrick, A. L., Mackey, R. H., Cai, T., Lopez, O. L., Kuller, L. H., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.9250 · Cited by 34
Integration of iPSC-Derived Microglia into Brain Organoids for Neurological Research
Mrza, M. A., He, J., & Wang, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063148 · Cited by 34
“TREM2 and SORL1 are both genes associated with APOE microglia [82,83 While GWAS has identi fi ed numerous AD-associated genes [81], there is limited direct evidence to conclusively con fi rm their contributions to the onset mechanisms of AD.”
BackgroundAPOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer’s disease
Brookhouser, N., Raman, S., Frisch, C., Srinivasan, G., & Brafman, D. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01076-3 · Cited by 33
“Although a vast majority of AD cases are sporadic, numerous genetic risk factors have been identified that contribute to lifetime risk of developing the disease [1].”
BackgroundRelationship Between Genetic Risk Factors and Markers for Alzheimer’s Disease Pathology
Elias-Sonnenschein, L. S., Bertram, L., & Visser, P. J. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.56 · Cited by 29
Self-citationLin, K., Chen, S., Lai, L., Huang, Y., Chen, J., Chen, T., Sun, Y., Wen, L., Yip, P., Chu, Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020573 · Cited by 33
“Limited vascular susceptibility genes were identified in a previous genome-wide association studies (GWAS) for AD risk [8].”
BackgroundJiang, S., & Bhaskar, K. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161123 · Cited by 30
APOE and metabolic dysfunction in Alzheimer's disease
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.02.002 · Cited by 31
St‐Pierre, M., VanderZwaag, J., Loewen, S. M., & Tremblay, M. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.932572 · Cited by 29
Zhang, Y., Lu, T., Yan, H., Ruan, Y., Wang, L., Zhang, D., Yue, W., & Lü, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056732 · Cited by 29
“PGBD1 has been reported to be a susceptibility gene for both schizophrenia and Alzheimer’s disease [27,35].”
BackgroundApolipoproteins and Alzheimer's pathophysiology
Koch, M., DeKosky, S. T., Fitzpatrick, A. L., Furtado, J. D., Lopez, O. L., Kuller, L. H., Mackey, R. H., Hughes, T. M., Mukamal, K. J., & Jensen, M. K. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.07.001 · Cited by 26
“Given the very strong associations of allelic differences in genes encoding apolipoproteins with risk of AD [2,20], it is perhaps surprising that few studies have assessed the associations of apolipoproteins in the circulation with ß-amyloid deposition and neurodegeneration.”
BackgroundHassan, M., Abbas, Q., Seo, S., Shahzadi, S., Alashwal, H., Zaki, N., Iqbal, Z., & Moustafa, A. A. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9044 · Cited by 29
“Genome-wide association studies have demonstrated that mutations in genetic material are frequently associated with AD, and mutations in specific genes are considered to be risk factors for the development of AD (13).”
BackgroundModeling Neurological Disorders with Human Pluripotent Stem Cell-Derived Astrocytes
Suga, M., Kondo, T., & Inoue, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163862 · Cited by 28
“Most cases of AD are late-onset sporadic AD, 1–2% are early-onset familial AD with underlying gene mutations in amyloid precursor protein (APP) or presenilin-1 and -2 (PSEN1/2) [67].”
BackgroundMyelin Lipid Alterations in Neurodegenerative Diseases: Landscape and Pathogenic Implications
Xu, Z., He, S., Begum, M. M., & Han, X. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0676 · Cited by 27
“As a lipid transport protein, the e 4 allele of ApoE is a major genetic risk factor for late-onset AD, accounting for over 95% of total cases (Aslam et al., 2023; Bertram and Tanzi, 2009; Cedazo-Minguez and Cowburn, 2001).”
Organophosphates Induced Alzheimer's Disease: An Epigenetic Aspect
Yadav, S. S., Singh, M. K., & Yadav, R. S. (2016) · Journal of Clinical Epigenetics · Cited by 27
Modern approaches to investigating non‐neuronal aspects of Alzheimer's disease
Liddelow, S. A. (2019) · The FASEB Journal · doi:10.1096/fj.201802592 · Cited by 27
The clinical utility of gene testing for Alzheimer’s disease
Atkins, E., & Panegyres, P. K. (2011) · Neurology International · doi:10.4081/ni.2011.e1 · Cited by 26
Chib, S., Dutta, B. J., Chalotra, R., Abubakar, M., Kumar, P., Singh, T. G., & Singh, R. (2024) · Phytotherapy Research · doi:10.1002/ptr.8406 · Cited by 25
Savonenko, A. V., Melnikova, T., Li, T., Price, D. L., & Wong, P. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00021-5 · Cited by 24
Dwomoh, L., Rossi, M., Scarpa, M., Khajehali, E., Molloy, C., Herzyk, P., Mistry, S. N., Bottrill, A. R., Sexton, P. M., Christopoulos, A., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abm3720 · Cited by 24
“The emergence of an array of AD risk factors from genome-wide association studies (11, 41, 42) has provided a number of potential targets that are distinct from the extensively tested β - and γ -secretase inhibitors and antibodies that target A β (6–8).”
Zeng, F., Zou, H., Zhou, H., Li, J., Wang, L., Cao, H.-Y., Yi, X., Wang, X., Liang, C., Wang, Y., et al. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.06.061 · Cited by 24
iPSC-derived PSEN2 (N141I) astrocytes and microglia exhibit a primed inflammatory phenotype
Sullivan, M. A., Lane, S. D., McKenzie, A. D. J., Ball, S. R., Sunde, M., Neely, G. G., Moreno, C. L., Maximova, A., Werry, E. L., & Kassiou, M. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02951-2 · Cited by 23
“Within the CNS, APOE is a lipid transport protein acting as a ligand for low density lipoprotein receptor and primarily produced by astrocytes and is the highest genetic risk factor for sAD [1, 70].”
BackgroundDing, Y., Palecek, S. P., & Shusta, E. V. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00580-2 · Cited by 23
“These BBB pathologies are more pronounced in patients that are APOE4 carriers [52], including more severe BBB breakdown [21, 53, 54], accelerated degeneration of brain pericytes [55–57], increased amyloid deposition [24], and worsened cognitive decline [58, 59].”
BackgroundCifuentes, R., & Murillo-Rojas, J. (2014) · BioMed Research International · doi:10.1155/2014/791238 · Cited by 23
“These two subnetworks were connected by the growth factor receptor-bound protein (GRB2), the unique intermediate node that had a nonsignificant 𝑧-score due to low specificity because of its many links (Table 3), in other words, because it is a molecule involved in many cellular processes [41].”
BackgroundInfluentialPerformance Metrics for Selecting Single Nucleotide Polymorphisms in Late-onset Alzheimer’s Disease
Chen, Y., Hsiao, C.-J., Jung, C.-C., Hu, H., Chen, J.-H., Lee, W., Chiou, J., Chen, T., Sun, Y., Wen, L.-L., et al. (2016) · Scientific Reports · doi:10.1038/srep36155 · Cited by 22
Human Glucose Transporters in Health and Selected Neurodegenerative Diseases
Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157392 · Cited by 21
“Two copies of the ApoE-ε 4 gene increase the risk of AD 12-fold, and one copy increases the risk of AD 4-fold [178].”
Sapkota, S., & Dixon, R. A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170909 · Cited by 21
“Recent studies have identified additional single nucleotide polymorphisms (SNPs) that may play an important role in AD development [26].”
The Genetics of Alzheimer’s Disease in the Chinese Population
Gan, C., Zhang, T., & Lee, T. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072381 · Cited by 21
“Omics” in traumatic brain injury: novel approaches to a complex disease
Hamdeh, S. A., Tenovuo, O. S., Peul, W. C., & Marklund, N. (2021) · Acta Neurochirurgica · doi:10.1007/s00701-021-04928-7 · Cited by 22
“Candidate SNPs have been successfully identified with GWAS in neurological disorders [8, 116].”
BackgroundGaj, P., Paziewska, A., Bik, W., Dąbrowska, M., Baranowska-Bik, A., Styczyńska, M., Chodakowska-Żebrowska, M., Pfeffer-Baczuk, A., Barcikowska, M., Baranowska, B., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120520 · Cited by 21
“Early onset familial Alzheimer’s disease (EOFAD) is constituted of patients diagnosed with AD before the age of 50–65, while in patients with late onset Alzheimer’s disease (LOAD), the first symptoms of dementia appear after 65 years of age [1].”
Cortical astroglia undergo transcriptomic dysregulation in the G93A SOD1 ALS mouse model
Miller, S., Glatzer, J. C., Hsieh, Y.-C., & Rothstein, J. D. (2018) · Journal of Neurogenetics · doi:10.1080/01677063.2018.1513508 · Cited by 20
From Genetics to Postgenomics and the Discovery of the New Social Body
Lock, M. M. (2012) · Duke University Press eBooks · doi:10.1215/9780822395478-009 · Cited by 20
New Approaches to the Pathology and Genetics of Neurodegeneration
Feany, M. Β. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091077 · Cited by 19
Bae, J., Logan, P. E., Acri, D. J., Bharthur, A., Nho, K., Saykin, A. J., Risacher, S. L., Nudelman, K., Polsinelli, A. J., Pentchev, V., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13319 · Cited by 18
Ramos de Matos, M., Ferreira, C., Herukka, S.-K., Soininen, H., Janeiro, A., Santana, I., Baldeiras, I., Almeida, M. R., Lleó, A., Dols-Icardo, O., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180512 · Cited by 18
Tong, G., Izquierdo, P., & Raashid, R. A. (2017) · The Open Neurology Journal · doi:10.2174/1874205x01711010027 · Cited by 18
“Despite having a strong heritable element, genome-wide association studies (GWAS) on SAD models have only reported 21 risk loci of varying consistency, with apolipoprotein isoform E4 (APOE4) and apolipoprotein J being most consistent [13, 14].”
BackgroundWu, P.-C., Fann, M., Tran, T. T., Chen, S.-C., Devina, T., Cheng, I. H.-J., Lien, C., Kao, L., Wang, S., Fuh, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55614-9 · Cited by 18
Neurogenetic and Neuroepigenetic Mechanisms in Cognitive Health and Disease
Coda, D. M., & Gräff, J. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.589109 · Cited by 18
Genome-Wide Association Study of Potential Meat Quality Trait Loci in Ducks
Guo, Q., Huang, L., Bai, H., Wang, Z., Bi, Y., Chen, G., Jiang, Y. Q., & Chang, G. (2022) · Genes · doi:10.3390/genes13060986 · Cited by 18
Xue, X., Zhang, M., Lin, Y., Xu, E., & Jia, J. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.11.042 · Cited by 17
Unraveling the biological mechanisms in Alzheimer's disease — Lessons from genomics
Borovečki, F., Klepac, N., Mück‐Šeler, D., Hajnšek, S., Mubrin, Z., & Pivac, N. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.019 · Cited by 17
“…pathways, including those involved in Aβ production, such as SORL1, GAB2 or CH25H (Andersen et al., 2005; Zerbinatti et al., 2008), aggregation, such as CST3 or PRNP (Kaeser et al., 2007; Schwarze-Eicker et al., 2005), and clearance, such as ACE (Bertram and Tanzi, 2009; Sleegers et al., 2010).”
BackgroundResultInfluentialAre We Prepared to Deal With the Alzheimer's Disease Pandemic?
Holtzman, J. L. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.84 · Cited by 17
Serbinek, D., Ullrich, C., Pirchl, M., Hochstrasser, T., Schmidt‐Kastner, R., & Humpel, C. (2010) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2010/106123 · Cited by 17
“It is notable that two of the major risk genes for late-onset AD, that is, APOE and CLU/Clusterin [41], have important functions in astrocytes [42, 43], and gene variants could relate to reduced glial functions.”
Anthropology and the Study of Disability Worlds
Rapp, R., & Ginsburg, F. (2012) · Duke University Press eBooks · doi:10.1215/9780822395478-011 · Cited by 18
Retromer dysfunction at the nexus of tauopathies
Carosi, J. M., Denton, D., Kumar, S., & Sargeant, T. J. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00727-2 · Cited by 16
Zhou, X., Kedia, S., Meng, R., & Gerstein, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312848 · Cited by 16
Plasma Sphingomyelins in Late-Onset Alzheimer’s Disease
Fote, G., Wu, J., Mapstone, M. E., Macciardi, F. M., Fiandaca, M. S., & Federoff, H. J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200871 · Cited by 16
Zhou, X., Azimi, M., Handin, N., Riselli, A. M., Vora, B., Chun, E., Dang, Z., Huang, E. J., Yee, S. W., Artursson, P., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-31224-6 · Cited by 15
Neurogenetic effects on cognition in aging brains: a window of opportunity for intervention?
Reinvang, I., Deary, I. J., Fjell, A. M., Steen, V. M., Espeseth, T., & Parasuraman, R. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00143 · Cited by 15
Hossini, A. M., Megges, M., Prigione, A., Lichtner, B., Toliat, M. R., Wruck, W., Schröter, F., Nüernberg, P., Kroll, H., Makrantonaki, E., et al. (2015) · BMC Genomics · doi:10.1186/s12864-015-1537-x · Cited by 15
Saraceno, G. F., Abrego-Guandique, D. M., Cannataro, R., Caroleo, M. C., & Cione, E. (2024) · BioMedInformatics · doi:10.3390/biomedinformatics4010033 · Cited by 15
Decoding molecular mechanisms: brain aging and Alzheimer’s disease
Hayat, M., Syed, R. A., Qaiser, H., Uzair, M., Al-Regaiey, K., Khallaf, R. A., Albassam, L. A. M., Kaleem, I., Wang, X., Wang, R., et al. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01403 · Cited by 14
Zou, F., Belbin, O., Carrasquillo, M. M., Culley, O. J., Hunter, T. A., Ma, L., Bisceglio, G. D., Allen, M., Dickson, D. W., Graff‐Radford, N. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064802 · Cited by 14
“The genetic locus encoding GRB-associated binding protein 2 (GAB2) is an example of a candidate gene that has shown relatively consistent replication in eleven published studies since its identification in 2007 [12] and still remains a strong LOAD candidate [13].”
BackgroundZhang, X., Veturi, Y., Verma, S. S., Bone, W. P., Verma, A., Lucas, A., Hebbring, S. J., Denny, J. C., Stanaway, I. B., Jarvik, G. P., et al. (2018) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789813279827_0025 · Cited by 14
Zeng, F., Deng, Y., Yi, X., Cao, H.-Y., Zou, H., Wang, X., Liang, C., Wang, Y., Zhang, L.-L., Gao, C., et al. (2013) · Neuroreport · doi:10.1097/wnr.0b013e3283619f43 · Cited by 14
Genetic Biomarkers in Alzheimer’s Disease
Khan, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804832-0.00004-3 · Cited by 14
Khan, M. I., Shin, J. H., Kim, M. Y., Shin, T. S., & Kim, J. D. (2020) · Molecules · doi:10.3390/molecules25102334 · Cited by 13
“General symptoms in the initial stages usually manifest before the age of 65 and involve memory loss, confusion, speech problems, and delusions [2].”
Effects of Blood Pressure Changes on Alzheimer’s Disease
Feldstein, C. A. (2010) · Neuroepidemiology · doi:10.1159/000316872 · Cited by 13
Grafting Together Medical Anthropology, Feminism, and Technoscience
Martin, E. (2012) · Duke University Press eBooks · doi:10.1215/9780822395478-003 · Cited by 14
Braudeau, J., Souchet, B., & Streel, E. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100107 · Cited by 12
Aghajanpour-Mir, M., Amjadi‐Moheb, F., Dadkhah, T., Hosseini, S. R., Ghadami, E., Assadollahi, E., Akhavan‐Niaki, H., & Ahangar, A. A. (2018) · Molecular Biology Reports · doi:10.1007/s11033-018-4561-5 · Cited by 12
Stearns, J., Burgoon, R., Sahadak, Z., Alazar, B., & Eng, M. L. (2021) · INNOVATIONS in pharmacy · doi:10.24926/iip.v12i3.2396 · Cited by 12
CR1 is potentially associated with rate of decline in sporadic Alzheimer’s disease
Schmidt, C., Wolff, M., von Ahsen, N., Lange, K., Friede, T., & Zerr, I. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.03.015 · Cited by 12
“Regarding genetic factors, genome wide association studies have revealed a multitude of single nucleotide polymorphisms (SNP) associated with sporadic AD risk [2].”
BackgroundIdentification of polymorphisms in cancer patients that differentially affect survival with age
Doherty, A., Kernogitski, Y., Kulminski, A. M., & de Magalhães, J. P. (2017) · Aging · doi:10.18632/aging.101305 · Cited by 12
“In ABCA7, seven SNPs (including rs4147918) are cholesterol-related and showed a significant association with Late Onset Alzheimer’s Disease [21], although little else is reported on the clinical effects caused by this polymorphism.”
BackgroundShcC proteins: Brain aging and beyond
Sagi, O., Budovsky, A., Wolfson, M., & Fraifeld, V. E. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.11.002 · Cited by 11
Argentati, C., Tortorella, I., Bazzucchi, M., Emiliani, C., Morena, F., & Martino, S. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030115 · Cited by 11
“The amyloid cascade hypothesis is based on the observation that at least 10–15% of AD patients have an inherited genetic background, while most of the cases (85–90%) are sporadic [4,8].”
BackgroundJain, A., & Roy, P. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.112902 · Cited by 11
Ghalayini, J., & Boulianne, G. L. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1166973 · Cited by 11
“Individuals carrying the apoE e4 allele have up to a 12-fold increased risk of developing the disease (Bertram and Tanzi, 2009).”
BackgroundZhang, Z., Fang, P., Shi, M., Zhu, Y. N., & Bo, P. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.08.001 · Cited by 11
“To the best of our knowledge, GALP is known to play a role in the control of feeding and body weight, which might indirectly affect the susceptibility to Late-onset Alzheimer's disease (Belbin et al., 2011; Bertram and Tanzi, 2009; Grupe et al., 2007; Schjeide et al., 2009).”
Liu, Q., Chen, C., Gao, A., Tong, H., & Xie, L. (2017) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2017.8217995 · Cited by 11
“The modulation of EGFR [23] and FGF [36] have been reported to be potential therapy for the AD.”
MethodInfluentialBedford, L. M., Tutrow, K. D., Hooper, K., Messenger, E. J., Hernandez, M., Lamb, B. T., Meyer, J. S., Richardson, T. I., & Bissel, S. J. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70772 · Cited by 10
Ananth, M. R., Gardus, J. D., Huang, C., Palekar, N., Slifstein, M., Záborszky, L., Parsey, R. V., Talmage, D. A., DeLorenzo, C., & Role, L. W. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115249 · Cited by 10
“43,45 In the present study, in evaluated samples, we find a higher occurrence of ε 4 heterozygotes in the OA-I group as compared to the OA group, consistent with the potential for elevated risk of cognitive impairment in ε 4 carriers.”
Presenilin-2 polymorphisms and risk of sporadic AD: Evidence from a meta-analysis
Chen, C., Zhou, Z., Li, M., Qu, M., Ma, Q., Zhong, M., Zhang, Y., & Yu, Z. (2012) · Gene · doi:10.1016/j.gene.2012.05.005 · Cited by 10
“There are two major types of AD, familial AD (FAD) that follows a relatively predictable inheritance pattern, and sporadic ADwith no obvious inheritance pattern (Bertram and Tanzi, 2009).”
BackgroundWang, K., Yuan, Y., Zhu, B., Zhang, Y., Wei, Y.-F., Meng, F.-S., Zhang, S., Wang, J., Zhou, J., & Initiative, A. D. N. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1277731 · Cited by 9
Varietas: a functional variation database portal
Paananen, J., Ciszek, R., & Wong, G. (2010) · Database · doi:10.1093/database/baq016 · Cited by 9
The Genetic Basis of Alzheimer's Disease
Hooli, B. V., & Tanzi, R. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00034-2 · Cited by 9
Self-citationChuang, Y., Varma, V. R., An, Y., Tanaka, T., Davatzikos, C. A., Resnick, S. M., & Thambisetty, M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191335 · Cited by 8
Obesity and the brain: a possible genetic link
Bertram, L., & Heekeren, H. R. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt51 · Cited by 8
Self-citationAmylin Pharmacology in Alzheimer’s Disease Pathogenesis and Treatment
Casadesús, G., Corrigan, R. R., & Piontkivska, H. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211201093147 · Cited by 7
“These findings were confirmed by others [146] (after adjusting for APOE4 allele, diabetes, stroke, kidney function and lipid profile [147].”
Aging, cognitive decline, apolipoprotein E and docosahexaenoic acid metabolism
Plourde, M. (2018) · OCL · doi:10.1051/ocl/2018032 · Cited by 7
“In humans, E4 is the most important genetic risk of AD (Coon et al., 2007, Bertram and Tanzi, 2009) and hAPOE4 mice have memory decline similar to that reported in humans (Bour et al., 2008; Siegel et al., 2010).”
ResultParker, R. (2012) · Duke University Press eBooks · doi:10.1215/9780822395478-013 · Cited by 7
INTRODUCTION: Medical Anthropology at the Intersections
Inhorn, M. C., & WENTZELL, E. A. (2012) · Duke University Press eBooks · doi:10.1215/9780822395478-001 · Cited by 7
Singers, M. (2012) · Duke University Press eBooks · doi:10.1215/9780822395478-012 · Cited by 7
Commentary: BAG3 as a Mediator of Endosome Function and Tau Clearance
Lin, H., Deaton, C. A., & Johnson, G. V. W. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.002 · Cited by 7
Zeman, T., Balcar, V. J., Cahová, K., Janoutová, J., Janout, V., Lochman, J., & Šerý, O. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02153-4 · Cited by 6
Dementia and the Health of the Nation
Larner, A. J. (2018) · In clinical practice · doi:10.1007/978-3-319-75723-0_1 · Cited by 6
Ahmed, S., & Miller, W. T. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102664 · Cited by 6
“Genome-wide association studies of Alzheimer’s disease have suggested a linkage with Tnk1 (9).”
The Genetic Basis of Alzheimer’s Disease
Hooli, B. V., & Tanzi, R. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00002-2 · Cited by 6
Self-citationDonev, R., & Howell, O. W. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-394287-6.00004-5 · Cited by 5
Goldstein, L. S. B., & Das, U. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.08.001 · Cited by 5
Genetic and Blood Biomarkers of Alzheimer`s Disease
Momeni, P., & Ferrari, R. (2010) · The Open Nuclear Medicine Journal · doi:10.2174/1876388x01002010012 · Cited by 5
“To date, there have been numerous studies on the genetics of AD and twelve GWAS and four other large scale studies catalogued in [12], reviewed by Bertram and Tanzi, 2009 [13]).”
BackgroundResultExplainable AI predicting Alzheimer’s disease with latent multimodal deep neural networks
Chen, X., Thompson, J. A., Yao, Z., Cappelleri, J. C., Amponsah, J. K., Mukherjee, R., & Hu, J. (2025) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2025.2511194 · Cited by 4
Gene Set Priorization Guided by Regulatory Networks with p-values through Kernel Mixed Model
Wang, H., López, O. L., Wu, W., & Xing, E. P. (2022) · Lecture notes in computer science · doi:10.1007/978-3-031-04749-7_7 · Cited by 4
Ohnuma, T., Nakamura, T., Takebayashi, Y., Hanzawa, R., Kitazawa, M., Higashiyama, R. I., Takeda, M., Thompson, K., Komatsu, M., Shimazaki, H., et al. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000345085 · Cited by 4
Li, J., Zhou, H., Deng, J., Zhu, J., Li, L., Zhang, M., Zeng, F., & Wang, Y. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.05.020 · Cited by 4
Li, J., Zeng, F., Deng, J., Zhu, J., Li, L., Zhang, T., Liu, J., Zhang, L., Gao, C., Zhang, M., et al. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9491-y · Cited by 4
“Genome-wide association studies (GWAS) have revealed that several SNPs within different genes, such as CLU, PICALM, and CR1, are closely related to the risk of sAD (Bertram and Tanzi, 2009), which strongly implicate the important role of genetic variation in the development of AD.”
BackgroundFeng, X., Yao, H., & Xiao, G. (2026) · Brain and Behavior · doi:10.1002/brb3.71267 · Cited by 3
“PGBD1, expressed in the brain and implicated in Alzheimer’s disease, highlights potential epigenetic mechanisms, though evidence for epilepsy remains limited (Bertram and Tanzi 2009 ; Schjeide et al. 2009 ).”
Gerónimo‐Olvera, C., Scheeler, S. M., Aguirre, C. G., Hormazabal, G. V., Garcia, D., Wu, L., Murad, N. F., Schneider, K., Wilson, K. A., Markov, N. T., et al. (2026) · Aging Cell · doi:10.1111/acel.70494 · Cited by 3
“Although several genetic risk factors for late-onset AD have been identified, APOE ε4 remains the strongest, increasing AD risk by ~fourfold with one allele and ~14-fold with two alleles relative to APOE ε3 homozygosity (Bertram and Tanzi 2009; Kamboh et al. 2012).”
Kumar, H. S., Moore, J. M., Steiner, A. C., Sotirakis, E., Schärli, B., Isnard, P., Thiam, K., Wolfer, D. P., & Böttger, E. C. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05031-z · Cited by 3
“Here, a possible clue behind Aβ accumulation points to polymorphisms in apolipoprotein E, which can influence aggregation and clearance of Aβ and are consistently identified as a risk factor for age-related AD [4, 47, 55].”
BackgroundCao, L., Wang, F., Ge, H., Wu, P.-C., Qü, P., Chen, G.-H., & Gao, Z.-L. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.12.026 · Cited by 3
“[4] L.”
Background
Metadata
- Authors
- Bertram, L., & Tanzi, R. E.
- Affiliations
- Max Planck Institute for Molecular Genetics (DE)
- Massachusetts General Hospital (US)
- Corresponding author
- Bertram, L.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-10-06
- Volume
- 18
- Issue
- R2
- Pages
- R137-R145
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC2758713
- OpenAlex
- W2164868723
- Cited by
- 257
- References
- 40
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 15 · 2023: 14 · 2022: 13 · 2021: 13 · 2020: 13 · 2019: 6 · 2018: 16 · 2017: 10 · 2016: 12 · 2015: 9 · 2014: 11 · 2013: 16 · 2012: 32
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease, genome-wide association study, genetic susceptibility loci, apolipoprotein E, Gab2, Galp, TNK1, clusterin, pathogenesis
- MeSH terms
- Alzheimer Disease, Humans, Genome, Human, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.